drugset / Trial / NCT04023149

Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris

NCT04023149

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical study will test the short-term efficacy of interleukin-2 gargle combined with systemic use of glucocorticoids in the treatment of oral mucosal lesions in mucosal-dominant pemphigus vulgaris and moderate mucocutaneous pemphigus vulgaris.

Timeline

Start
2020-04-02
Primary completion
2021-06-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Interleukin-2 Protein / enzyme biologic 2e+06 iu Other

Indications